Rocket Pharmaceuticals/$RCKT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rocket Pharmaceuticals
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Ticker
$RCKT
Sector
Primary listing
Employees
299
Headquarters
Website
RCKT Metrics
BasicAdvanced
$327M
-
-$2.49
0.65
-
Price and volume
Market cap
$327M
Beta
0.65
52-week high
$21.13
52-week low
$2.19
Average daily volume
4.5M
Financial strength
Current ratio
6.386
Quick ratio
6.256
Long term debt to equity
6.298
Total debt to equity
7.115
Interest coverage (TTM)
-139.85%
Profitability
EBITDA (TTM)
-253.866
Management effectiveness
Return on assets (TTM)
-38.07%
Return on equity (TTM)
-69.65%
Valuation
Price to book
0.92
Price to tangible book (TTM)
1.13
Price to free cash flow (TTM)
-1.517
Free cash flow yield (TTM)
-65.91%
Free cash flow per share (TTM)
-1.997
Growth
Earnings per share change (TTM)
-10.51%
3-year earnings per share growth (CAGR)
-5.66%
What the Analysts think about RCKT
Analyst ratings (Buy, Hold, Sell) for Rocket Pharmaceuticals stock.
Bulls say / Bears say
Rocket plans to conserve its $318.2 million cash reserves, which could fund operations through 2027 and support ongoing research and development in its gene therapy pipeline.
The company’s RP-A601 program for PKP2-ACM has received the FDA’s RMAT (Regenerative Medicine Advanced Therapy) designation, granting access to intensive guidance and potentially accelerated review that could speed up development and possible approval.
The FDA has cleared Rocket’s IND application for RP-A701 and granted Fast Track designation for its BAG3-DCM gene therapy candidate, expanding its clinical pipeline and strengthening its long-term growth outlook.
The FDA has paused Rocket’s Phase 2 pivotal trial of RP-A501 after a patient died from capillary leak syndrome, delaying a program seen as a major revenue source and raising safety concerns.
Rocket has announced it will lay off 30% of its workforce and will halt investment in its Fanconi Anemia and Pyruvate Kinase Deficiency programs, marking a contraction of its pipeline that could limit future diversification.
After news of the FDA's trial suspension was released, Rocket’s shares dropped more than 60%, highlighting deep investor skepticism and increased volatility around its main program.
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
RCKT Financial Performance
Revenues and expenses
RCKT Earnings Performance
Company profitability
RCKT News
AllArticlesVideos
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
Business Wire3 weeks ago
FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy
Benzinga4 weeks ago
Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease
Business Wire4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rocket Pharmaceuticals stock?
Rocket Pharmaceuticals (RCKT) has a market cap of $327M as of September 18, 2025.
What is the P/E ratio for Rocket Pharmaceuticals stock?
The price to earnings (P/E) ratio for Rocket Pharmaceuticals (RCKT) stock is 0 as of September 18, 2025.
Does Rocket Pharmaceuticals stock pay dividends?
No, Rocket Pharmaceuticals (RCKT) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Rocket Pharmaceuticals dividend payment date?
Rocket Pharmaceuticals (RCKT) stock does not pay dividends to its shareholders.
What is the beta indicator for Rocket Pharmaceuticals?
Rocket Pharmaceuticals (RCKT) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.